CA2202027A1 - Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same - Google Patents

Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Info

Publication number
CA2202027A1
CA2202027A1 CA002202027A CA2202027A CA2202027A1 CA 2202027 A1 CA2202027 A1 CA 2202027A1 CA 002202027 A CA002202027 A CA 002202027A CA 2202027 A CA2202027 A CA 2202027A CA 2202027 A1 CA2202027 A1 CA 2202027A1
Authority
CA
Canada
Prior art keywords
enteric bacterium
enteric
bacterium
shigella
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002202027A
Other languages
English (en)
French (fr)
Inventor
John L. Pace
Richard I. Walker
Steven M. Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/538,543 external-priority patent/US5681736A/en
Application filed by Individual filed Critical Individual
Publication of CA2202027A1 publication Critical patent/CA2202027A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/045Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002202027A 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same Abandoned CA2202027A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31840994A 1994-10-05 1994-10-05
US318,409 1994-10-05
US08/538,545 1995-10-03
US08/538,543 1995-10-03
US08/538,543 US5681736A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US08/538,545 US5679564A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic campylobacter bacteria and vaccines

Publications (1)

Publication Number Publication Date
CA2202027A1 true CA2202027A1 (en) 1996-04-18

Family

ID=27405987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002202027A Abandoned CA2202027A1 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Country Status (16)

Country Link
EP (1) EP0804542A4 (de)
JP (1) JP3394047B2 (de)
CN (1) CN1168693A (de)
AU (1) AU704283B2 (de)
BR (1) BR9509276A (de)
CA (1) CA2202027A1 (de)
CZ (1) CZ104397A3 (de)
FI (1) FI971403L (de)
HU (1) HUT77876A (de)
IL (1) IL115521A0 (de)
MX (1) MX9702431A (de)
NO (1) NO971519L (de)
NZ (1) NZ295907A (de)
PL (1) PL182700B1 (de)
SG (2) SG73510A1 (de)
WO (1) WO1996011258A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0792347B1 (de) * 1994-10-05 2005-11-23 Antex Biologics, Inc. Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
EP2327720A1 (de) * 2003-05-30 2011-06-01 Intercell AG Enterokokken-Antigene
US20100074846A1 (en) * 2006-03-17 2010-03-25 Ellis John A Campylobacter Vaccines and Methods of use
EP2161035B1 (de) * 2007-05-28 2019-08-21 Daiichi Sankyo Company, Limited Ganzzellige imfpstoffzusammensetzung mit bordetella parapertussis
CN107513553B (zh) * 2017-09-18 2021-05-18 江南大学 一种筛选具有拮抗空肠弯曲杆菌感染功能的乳酸菌的方法
CN109633151B (zh) * 2018-12-26 2022-03-11 西北农林科技大学 一种肠炎沙门氏菌检测方法、试纸条及应用
WO2020141103A1 (en) 2018-12-31 2020-07-09 Bellevacc As Bacterial vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI932248L (fi) * 1991-09-18 1993-07-02 Amgen Inc Hepatit b-vaccinkomposition innehaollande ett gallsyrasalt

Also Published As

Publication number Publication date
CZ104397A3 (cs) 1998-06-17
NO971519D0 (no) 1997-04-03
PL182700B1 (pl) 2002-02-28
EP0804542A1 (de) 1997-11-05
SG73510A1 (en) 2000-06-20
AU3956195A (en) 1996-05-02
EP0804542A4 (de) 1998-10-28
WO1996011258A1 (en) 1996-04-18
JPH10507347A (ja) 1998-07-21
FI971403A0 (fi) 1997-04-04
FI971403A7 (fi) 1997-06-04
JP3394047B2 (ja) 2003-04-07
HUT77876A (hu) 1998-09-28
AU704283B2 (en) 1999-04-15
SG73509A1 (en) 2000-06-20
NZ295907A (en) 1999-04-29
PL319580A1 (en) 1997-08-18
CN1168693A (zh) 1997-12-24
BR9509276A (pt) 1997-11-18
IL115521A0 (en) 1996-06-18
NO971519L (no) 1997-05-27
FI971403L (fi) 1997-06-04
MX9702431A (es) 1998-05-31

Similar Documents

Publication Publication Date Title
US6083683A (en) Methods for detecting shigella bacteria or antibodies to shigella bacteria with an immunoassay
Takai et al. Identification of 15-to 17-kilodalton antigens associated with virulent Rhodococcus equi
Ørskov et al. 4 serotyping of Klebsiella
Salajka et al. Colonization factor different from K88, K99, F41 and 987P in enterotoxigenic Escherichia coli strains isolated from postweaning diarrhoea in pigs
US6051416A (en) Methods for producing enhanced antigenic Helicobacter sp.
Tsang et al. A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide
WO1996011257A9 (en) Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same
Li et al. Reversible synthesis of colanic acid and O-antigen polysaccharides in Salmonella Typhimurium enhances induction of cross-immune responses and provides protection against heterologous Salmonella challenge
CA2202027A1 (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
WO1996011258A9 (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
JPH08502720A (ja) ネコ引っ掻き病および細菌性血管腫症の診断のための方法および組成物
Svenungsson et al. Synthetic disaccharide-protein antigens for production of specific 04 and 09 antisera for immunofluorescence diagnosis of Salmonella
Granström et al. Bordetella pertussis lipopolysaccharide as antigen in ELISA for serological diagnosis of whooping cough
Fang Intestinal Escherichia coli infections
Aziz Annotated bibliography on classical vibrio cholerae
Oranje Serological diagnosis of gonorrhoea using gonococcal pili as antigen
Lockman Motility and adherence as Salmonella typhimurium virulence factors: The pathogenesis of fla, mot, andfim mutants in murine typhoid fever
Cohen Operation of a Research Unit for Surveillance of Infectious Diseases and Development of Vaccines.
Kim Studies on Salmonella enteritidis: Epidemiologic, diagnostic, and prophylactic approaches to S. enteritidis infection
HK1005247A (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20071004